Editor's Pick
Sophia sponsored a meeting gathering early adopters, pharma partners, and others to discuss the recently launched MSK-ACCESS, and soon-to-launch MSK-IMPACT kits.
The nonprofit behind the work aims to bring the test to market in the next 18 to 24 months and is in discussions with potential commercialization partners.
Whole-Genome Sequencing Approach Enables Simultaneous Surveillance of Hospital-Associated Pathogens
Premium
Described in a proof-of-concept study, the method demonstrated the potential utility of pan-pathogen sequencing for monitoring hospital-associated infections.
Called optiPRM, the approach could help detect cancer neoantigens in patient tumor samples for applications like the development of personalized cancer vaccines.
Cancer Centers Look to New NGS-Based 'Frankenpanel' to Get Fast Info on Clinically Actionable Genes
Premium
Memorial Sloan Kettering Cancer Center is among the first healthcare systems to implement the rapid sequencing assay, which can consolidate single-gene tests.